Recombinant human IgA-J chain dimer
AssigneesBond of Regents, The University of Texas System, The United States of America as represented by the Department of Health and Human Services
InventorsJ. Donald Capra, Jonathan M. Hexham, Leon N. Carayannopoulos, Edward E. Max
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods of use that comprise engineered IgA antibodies that, when administered to a host are secreted across the epithelium into the mucosal barriers of the body providing external passive immunotherapy against agents such as viral, bacterial and eukaryotic pathogens. Also disclosed are mini antibodies comprising the minimal transcytosis domains.
Claims5
A method of inhibiting an infection by an infective agent in a subject comprising administering to said subject a dimeric mini-IgA antibody comprising a J chain linking two monomeric mini-IgA chains, each comprising a VH domain fused to a first IgA1 Cα3 domain including a tailpiece, and a VL domain fused to a second IgA1 Cα3 domain including a tailpiece, wherein said VL and VH domains constitute an antigen recognition site that is immunoreactive with said agent in an amount effective to inhibit said infection.
The method 1 wherein said agent is a virus.
Dependencies are inferred from the claim text.